

Pfizer Launches Third Integrated Annual Review

Monday, April 08, 2013 - 11:10pm

"At the core of our performance in 2012 were the actions we took resulting from the four imperatives that we put in place at the beginning of 2011,"

([BUSINESS WIRE](#))--Pfizer Inc. (NYSE: PFE) today announced the launch of its third integrated annual review (www.pfizer.com/annual) which summarizes the company's 2012 financial, environmental and social responsibility performance.

Pfizer Chairman and Chief Executive Officer Ian C. Read said in his annual letter to stakeholders that the company had a pivotal year for pipeline development, launching five new therapies and making significant progress in its early- and mid-stage pipeline. "At the core of our performance in 2012 were the actions we took resulting from the four imperatives that we put in place at the beginning of 2011," he said. "Through the focus they provided, we advanced our R&D turnaround, operated efficiently to create a more-flexible cost base, met our financial commitments, and maintained high standards of quality, compliance and business ethics.

Additionally, we made continued progress in our ongoing efforts to earn society's respect and to create an ownership culture within Pfizer. I believe our culture can become a key sustainable advantage as we work to make Pfizer the premier, innovative biopharmaceutical company."

Besides summarizing the company's financial performance, the annual review addresses the company's progress in other key performance indicators such as the number of top 20 diseases addressed by current and in-development Pfizer products, company efforts to improve access to medicines and publicly stated targets achieved in the reduction of greenhouse gases.

About Pfizer Inc.:

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.

Pfizer Inc. Media Relations: Jennifer Kokell, 212-733-2596 or Investor Relations Suzanne Harnett, 212-733-8009